Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs

European Journal of Pharmacology

Volumn 512, Issue 1, 2005, Pages 53-60

  Schneider, Johannes ^a   Hauser, Renate ^a   Andreas, Jens Otto ^a   Linz, Klaus ^a   Jahnel, Ulrich ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

(Dog); HERG; QT interval; Risk assessment

Indexed keywords

DOFETILIDE; POTASSIUM CHANNEL HERG; SOTALOL; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DOG; EVALUATION; HEART ARRHYTHMIA; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; STATISTICAL ANALYSIS; TORSADE DES POINTES;

EID: 16244402292     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.01.042     Document Type: Article

References (34)

1. C. Antzelevitch, and W. Shimizu Cellular mechanisms underlying the long QT syndrome Curr. Opin. Cardiol. 17 2002 43 51
2. (Ks)-blocking agent chromanol 293b on regional disparity of left ventricular repolarization in the intact canine heart J. Cardiovasc. Pharmacol. 39 2002 460 467
3. L. Belardinelli, C. Antzelevitch, and M.A. Vos Assessing predictors of drug-induced torsade de pointes Trends Pharmacol. Sci. 24 2003 619 625
4. B. Brendorp, O. Pedersen, C. Torp-Pedersen, N. Sahebzadah, and L. Kober A benefit-risk assessment of class III antiarrhythmic agents Drug Saf. 25 2002 847 865
5. M. Brennan, M. Palaniswami, and P. Kamen Do existing measures of Poincare plot geometry reflect nonlinear features of heart rate variability? IEEE Trans. Biomed. Eng. 48 2001 1342 1347
6. A. Bril, M.C. Forest, B. Cheval, and J.F. Faivre Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide Cardiovasc. Res. 37 1998 130 140
7. J.D. Buck, D.C. Warltier, H.F. Hardman, and G.J. Gross Effects of sotalol and vagal stimulation on ischemic myocardial blood flow distribution in the canine heart J. Pharmacol. Exp. Ther. 216 1981 347 351
8. L. Eckardt, G. Breithardt, and W. Haverkamp Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation J. Pharmacol. Exp. Ther. 300 2002 64 71
9. H. Elming, B. Brendorp, O.D. Pedersen, L. Kober, and C. Torp-Petersen Dofetilide: a new drug to control cardiac arrhythmia Expert Opin. Pharmacother. 4 2003 973 985
10. A.A. Fossa, M.J. Depasquale, D.L. Raunig, M.J. Avery, and D.J. Leishman The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment J. Pharmacol. Exp. Ther. 302 2002 828 833
11. A.A. Fossa, T. Wisialowski, E. Wolfgang, E. Wang, M. Avery, D.L. Raunig, and B. Fermini Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig Eur. J. Pharmacol. 486 2004 209 221
12. G.A. Gintant, J.T. Limberis, J.S. McDermott, C.D. Wegner, and B.F. Cox The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis J. Cardiovasc. Pharmacol. 37 2001 607 618
13. W. Haverkamp, G. Breithardt, A.J. Camm, M.J. Janse, M.R. Rosen, C. Antzelevitch, D. Escande, M. Franz, M. Malik, A. Moss, and R. Shah The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology Cardiovasc. Res. 47 2000 219 233
14. L.M. Hondeghem, and P. Hoffmann Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability J. Cardiovasc. Pharmacol. 41 2003 14 24
15. L.M. Hondeghem, L. Carlsson, and G. Duker Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic Circulation 103 2001 2004 2013
16. L.M. Hondeghem, H.R. Lu, K. van Rossem, and F. de Clerck Detection of proarrhythmia in the female rabbit heart: blinded validation J. Cardiovasc. Electrophysiol. 14 2003 287 294
17. Kr over other K+ currents in guinea-pig ventricular myocytes Br. J. Pharmacol. 131 2000 1809 1816
18. D.O. Kozhevnikov, K. Yamamoto, D. Robotis, M. Restivo, and N. El Sherif Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns Circulation 105 2002 1128 1134
19. C.P. Lau, A.R. Freeman, and S.J. Fleming Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate Cardiovasc. Res. 22 1988 67 72
20. J.J. Lynch, D.J. Wilber, D.G. Montgomery, T.M. Hsieh, E. Patterson, and B.R. Lucchesi Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol J. Cardiovasc. Pharmacol. 6 1984 1132 1141
21. P. Milberg, L. Eckardt, H.J. Bruns, J. Biertz, S. Ramtin, N. Reinsch, D. Fleischer, P. Kirchhof, L. Fabritz, G. Breithardt, L. Eckhardt, W. Haverkamp, and H.J. Bruns Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early after depolarizations and torsade de pointes J. Pharmacol. Exp. Ther. 303 2002 218 225
22. H. Numaguchi, F.M. Mullins, J.P. Johnson Jr., D.C. Johns, S.S. Po, I.C. Yang, G.F. Tomaselli, and J.R. Balser Probing the interaction between inactivation gating and Dd-sotalol block of HERG Circ. Res. 87 2000 1012 1018
23. W.S. Redfern, L. Carlsson, A.S. Davies, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K.S. Siegl, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45
24. M. Schoenmakers, C. Ramakers, J.M. Van Opstal, J.D. Leunissen, C. Londono, and M.A. Vos Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog Cardiovasc. Res. 59 2003 351 359
25. R.R. Shah The significance of QT interval in drug development Br. J. Clin. Pharmacol. 54 2002 188 202
26. W. Shimizu, B. McMahon, and C. Antzelevitch Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome J. Cardiovasc. Electrophysiol. 10 1999 154 164
27. D.J. Snyders, and A. Chaudhary High affinity open channel block by dofetilide of HERG expressed in a human cell line Mol. Pharmacol. 49 1996 949 955
28. P. Taggart, R. Donaldson, J. Abed, and F. Nashat Class III action of beta-blocking agents Cardiovasc. Res. 18 1984 683 689
29. M.B. Thomsen, C. Verduyn, M. Stengl, J.D.M. Beekman, G. de Pater, J. van Opstal, P.G.A. Volders, and M.A. Vos Increased short-term variability of repolarization predicts d-sotalol-induced Torsade de Pointes in dogs Circulation 110 2004 2453 2459
30. A. Van de Water, J. Verheyen, R. Xhonneux, and R.S. Reneman An improved method to correct the QT interval of the electrocardiogram for changes in heart rate J. Pharmacol. Methods 22 1989 207 217
31. J.M. Van Opstal, J.D. Leunissen, H.J. Wellens, and M.A. Vos Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias Eur. J. Pharmacol. 412 2001 67 76
32. M. Weerapura, T.E. Hebert, and S. Nattel Dofetilide block involves interactions with open and inactivated states of HERG channels Pflügers Arch. 443 2002 520 531
33. J. Weissenburger, J.M. Davy, F. Chezalviel, O. Ertzbischoff, J.M. Poirier, F. Engel, P. Lainee, E. Penin, G. Motte, and G. Cheymol Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol J. Pharmacol. Exp. Ther. 259 1991 871 883
34. S. Zhang, Z. Zhou, Q. Gong, J.C. Makielski, and C.T. January Mechanism of block and identification of the verapamil binding domain to HERG potassium channels Circ. Res. 84 1999 989 998